Trial Profile
POSTMARKETING OBSERVATIONAL STUDY OF THE IMPACT OF PREVNAR 13 (PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE) ON OTITIS MEDIA IN CHILDREN
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 Sep 2014 Planned number of patients changed from 0 to 391 as reported by ClinicalTrials.gov record.
- 14 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 14 Feb 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.